Therapeutic area intelligence for AL Amyloidosis with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 0

Companies

No related entities indexed yet.

Assets

daratumumab →

FKC289 →

Recent signals(2)

ClinicalAugust 16, 2026

FKC289 Phase I/II Study Initiated for Relapsed/Refractory AL Amyloidosis

Shenzhen Fosun Kairos Biotechnology Co., Ltd. has initiated Phase I/II clinical study to evaluate FKC289 in patients with relapsed/refractory primary AL amyloidosis, focusing on safety and efficacy.

ClinicalAugust 9, 2026

Impact of Dexamethasone Duration on AL Amyloidosis Treatment Outcomes

The study highlights the uncertainty surrounding the optimal duration of dexamethasone in treating newly diagnosed AL amyloidosis, especially with the introduction of daratumumab-based regimens.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.